BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23034090)

  • 1. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori.
    Haneda M; Kato M; Ishigaki S; Suzuki M; Takahashi M; Nakagawa M; Ono S; Mori Y; Mabe K; Nakagawa S; Kudo T; Shimizu Y; Asaka M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):78-83. PubMed ID: 23034090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study.
    Gisbert JP; Boixeda D; Al-Mostafa A; Vila T; de Rafael L; Alvarez Baleriola I; de Argila CM; Abraira V
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):189-200. PubMed ID: 10102232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical significance of GastroPanel in diagnostics of Helicobacter pylori eradication efficiency in patients with dyspepsia with correlation of family history of gastric cancer].
    Adamczyk M; Peczek Ł; Rudnicki C; Nawrot B; Stec-Michalska K
    Pol Merkur Lekarski; 2013 Sep; 35(207):141-7. PubMed ID: 24224450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
    Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
    Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
    Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
    Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
    Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up study on a high risk population of gastric cancer in north China by serum pepsinogen assay.
    Sun LP; Gong YH; Wang L; Gong W; Yuan Y
    J Dig Dis; 2008 Feb; 9(1):20-6. PubMed ID: 18251790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation about usefulness of serum antibody of Helicobacter pylori and serum pepsinogen I/II ratio as a marker of the judgment after eradication therapy].
    Fujisawa T; Kumagai T; Goto A; Fujimori K; Akamatsu T; Kiyosawa K
    Nihon Rinsho; 1999 Jan; 57(1):101-6. PubMed ID: 10036944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
    Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
    Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term dynamics of gastric biomarkers after eradication of Helicobacter pylori infection.
    Daugule I; Ruskule A; Moisejevs G; Rudzite D; Jonaitis L; Janciauskas D; Kiudelis G; Kupcinskas L; Leja M
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):501-5. PubMed ID: 25822857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication.
    Shiotani A; Uedo N; Iishi H; Yoshiyuki Y; Ishii M; Manabe N; Kamada T; Kusunoki H; Hata J; Haruma K
    Digestion; 2008; 78(2-3):113-9. PubMed ID: 19023205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of serum pepsinogen in functional dyspepsia.
    Tahara T; Shibata T; Okubo M; Yamashita H; Yoshioka D; Yonemura J; Maruyama N; Kamano T; Kamiya Y; Fujita H; Nakagawa Y; Nagasaka M; Iwata M; Yamada H; Nakamura M; Arisawa T; Hirata I
    Hepatogastroenterology; 2012; 59(120):2516-22. PubMed ID: 23178618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
    Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
    Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
    Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H. pylori virulence factors in a paediatric population.
    Lopes AI; Palha A; Lopes T; Monteiro L; Oleastro M; Fernandes A
    Scand J Gastroenterol; 2006 May; 41(5):524-31. PubMed ID: 16638693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients.
    Ohkusa T; Miwa H; Nomura T; Asaoka D; Kurosawa A; Sakamoto N; Abe S; Hojo M; Terai T; Ogihara T; Sato N
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():25-32. PubMed ID: 15298602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Serum Pepsinogens and Helicobacter Pylori Infection with High-Sensitivity C-Reactive Protein in Medical Examination Population.
    Liu H; Fei C; Zhang J
    Lab Med; 2021 Jan; 52(1):57-63. PubMed ID: 32702129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.
    Al-Assi MT; Miki K; Walsh JH; Graham DP; Asaka M; Graham DY
    Am J Gastroenterol; 1999 Sep; 94(9):2367-72. PubMed ID: 10483993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between abnormal gastric function risk and Helicobacter pylori infection assessed by ELISA and 14C-urea breath test.
    Gong Y; Wei W; Yuan Y
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):316-20. PubMed ID: 25284372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.